159002-15-0

Usage

Uses

Used in Pharmaceutical Development:
N-CBZ-3-N-BOC-AMINO-ALANINE is used as a key building block in the synthesis of pharmaceuticals for its role in creating specific peptide sequences with desired properties. The protective groups allow for precise manipulation during the synthesis process, which is essential for developing new drugs with targeted therapeutic effects.
Used in Biotechnology Applications:
In the biotechnology industry, N-CBZ-3-N-BOC-AMINO-ALANINE is utilized as a component in the design and synthesis of bioactive peptides. Its ability to be selectively deprotected and functionalized contributes to the development of peptides with specific biological activities, which can be used in various applications such as diagnostics, therapeutics, and research tools.
Used in Peptide Synthesis Research:
N-CBZ-3-N-BOC-AMINO-ALANINE serves as a research tool in the field of peptide synthesis, where its protective groups facilitate the exploration of new synthetic methods and the development of novel peptide-based compounds. N-CBZ-3-N-BOC-AMINO-ALANINE is instrumental in advancing the understanding of peptide chemistry and its applications in various scientific and industrial fields.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 173259-63-7 (R)-tert-butyl-N-<(3-benzyloxycarbonyl-5-oxo-4-oxazolidinyl)-methyl>carbamate 
• 62234-37-1 2-(R)-amino>-3-aminopropionic acid 
• 4474-86-6 (R)-4-amino-2-(((benzyloxy)carbonyl)amino)-4-oxobutanoic acid 
• 501-53-1 benzyl chloroformate 
• 135841-16-6 (R)-3-benzyloxycarbonyl-5-oxo-4-oxazolidinoneacetic acid 

Downstream Products

• 58457-98-0 methyl (2S)-2-{[(benzyloxy)carbonyl]amino}-3-[(tert-butoxycarbonyl)amino]propanoate 
• 173259-64-8 (R)-2-benzyloxycarbonylamino-3-tert-butoxycarbonylamino-N-methoxy-N-methylpropanamide 
• 96136-12-8 2-benzyloxycarbonylamino-3-tert-butoxycarbonylamino-propionic acid methyl ester 
• 96186-29-7 methyl D-3-<(benzyloxycarbonyl)amino>-4-<(tert-butoxycarbonyl)amino>butyrate 
• 96186-30-0 D-3-<(benzyloxycarbonyl)amino>-4-<(tert-butoxycarbonyl)amino>butyric acid 
• 261367-91-3 (3-tert-butoxycarbonylamino-2-phenylmethanesulfonylamino-propionylamino)-acetic acid ethyl ester 
• 259825-43-9 (R)-2-amino-3-((tert-butoxycarbonyl)amino)propanoic acid 
• 261367-85-5 (2-benzyloxycarbonylamino-3-tert-butoxycarbonylamino-propionylamino)-acetic acid ethyl ester 
• 91289-64-4 C₁₉H₂₆N₂O₈ 

Relevant academic research and scientific papers

PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR

The present invention is directed to novel prodrugs of modulators of the NMDA receptor of formula I. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.

ETHER DERIVATIVE

The present invention relates to an ether derivative represented by the formula (I), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof wherein each symbol is as defined in the description, and an ether derivative represented by the formula (III), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof wherein each symbol is as defined in the description; a pharmaceutical composition containing the ether derivative; and a package containing the pharmaceutical composition and a description of use thereof. A pharmaceutical composition of the present invention, which contains this compound of the present invention has a superior anti-inflammatory and analgesic activity and is useful as various pharmaceutical agents such as an anti-inflammatory agent, an analgesic, a therapeutic agent for inflammatory bowel disease, a therapeutic agent for pollakiuria and/or incontinentia, a therapeutic agent for asthma and the like.

Synthesis of alanine and proline amino acids with amino or guanidinium substitution on the side chain

Competitive binding of peptides containing basic amino acids to disrupt or prevent the Tat-TAR interaction could result in diminished transcription as well as translation and hence constitutes an alternative way of controlling HIV replication. Therefore, we synthesized guanidinium and amino containing amino acids, based on a proline or an alanine scaffold. The introduction of the guanidinium moiety was best accomplished using 1H- pyrazole-1-carboxamidine hydrochloride, with Pmc used for its protection. The absence of racemization, maintained throughout the whole synthesis, was confirmed by chiral purity determination. These building blocks were smoothly incorporated into oligopeptides, which proved their suitability for use in a combinatorial approach for selecting TAR binding ligands. (C) 2000 Elsevier Science Ltd.

Exploratory solid-phase synthesis of factor Xa inhibitors: Discovery and application of P3-heterocyclic amides as novel types of non-basic arginine surrogates

A series of novel FXa inhibitors 2a-m and 3a-f was discovered that feature heterocyclic carboxamides tethered to a d-diaminobutyric acid sidechain. These neutral amide derivatives serve as novel P3 d-arginine mimics. Pyrazine carboxamide scaffolds afforded the most potent FXa inhibitors (e.g., 2b IC50 = 4.6 nM). The synthesis and biological activity of two focused libraries are reported.

Synthesis of crystalline orthogonally N-protected (S)- or (R)-2,3-diaminopropionaldehyde from L- or D-aspartic acid

Procedures are described for the easy preparation of crystalline orthogonally N-protected (S)- or (R)-2,3-diaminopropionaldehyde of high optical purity from L- or D-aspartic acid, respectively, and in reasonable yields.